Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.

@article{Harder2013IntravitrealBF,
  title={Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.},
  author={Bjoern C. Harder and Frank C. Schlichtenbrede and Stefan von Baltz and Waldemar Jendritza and Bettina B Jendritza and Jost Bruno Jonas},
  journal={American journal of ophthalmology},
  year={2013},
  volume={155 6},
  pages={1119-1124.e1}
}
PURPOSE To evaluate refractive error in infants who underwent intravitreal bevacizumab injection for treatment of threshold retinopathy of prematurity (ROP). DESIGN Retrospective nonrandomized interventional comparative study. METHODS The study group included all infants who consecutively received a single intravitreal bevacizumab (0.375 mg or 0.625 mg) injection for therapy of threshold ROP in fundus zone I or zone II. The control group included infants who had previously undergone retinal… CONTINUE READING
36 Citations
16 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Early refractive outcome after intravitreal bevazicumab for retinopathy of prematurity

  • BC Harder, S von Baltz, FC Schlichtenbrede, JB. Jonas
  • Arch Ophthalmol
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…